Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H F Dullens

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Glycobiology|February 1, 1993
Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chainsH Voshol, H F Dullens, W Den Otter, et al.
Cellular Immunology|September 1, 1986
Higher ADCC of murine peritoneal cells after immunization with allogenic tumor cells as compared with stimulation by adriamycin, BCG, and thioglycolateH J Haisma, M Ligtenberg, H F Dullens, et al.
European Journal of Immunology|June 1, 1974
Site-dependent differences in rejection of tumor cells with and without preimmunizationW den Otter, B A Runhaar, A Ruitenbeek, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|July 1, 1995
Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2M R Bernsen, H F Dullens, W Den Otter, et al.
Journal of Experimental Therapeutics & Oncology|July 1, 1996
The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administrationL A Everse, M R Bernsen, H F Dullens, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Priming of the antitumor response promotes efficacy of interleukin-2 therapyL A Everse, M R Bernsen, H F Dullens, et al.
European Journal of Cancer|January 1, 1979
Anti-tumour effect of chlorambucil-antibody complexes in a murine melanoma systemH F Dullens, R A De Weger, C Vennegoor, et al.
Infection and Immunity|December 1, 1985
Antibacterial resistance, macrophage influx, and activation induced by bacterial rRNA with dimethyldioctadecylammonium bromideR Gonggrijp, W J Mullers, H F Dullens, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive miceH F Dullens, W Vuist, M Van der Maas, et al.
Journal of the National Cancer Institute|January 1, 1975
Therapy with antibody-coated immune and hyperimmune peritoneal cells in a murine lymphoma systemH F Dullens, R A De Weger, R A Woutersen, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Glycobiology|February 1, 1993
Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chainsH Voshol, H F Dullens, W Den Otter, et al.
Cellular Immunology|September 1, 1986
Higher ADCC of murine peritoneal cells after immunization with allogenic tumor cells as compared with stimulation by adriamycin, BCG, and thioglycolateH J Haisma, M Ligtenberg, H F Dullens, et al.
European Journal of Immunology|June 1, 1974
Site-dependent differences in rejection of tumor cells with and without preimmunizationW den Otter, B A Runhaar, A Ruitenbeek, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|July 1, 1995
Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2M R Bernsen, H F Dullens, W Den Otter, et al.
Journal of Experimental Therapeutics & Oncology|July 1, 1996
The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administrationL A Everse, M R Bernsen, H F Dullens, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Priming of the antitumor response promotes efficacy of interleukin-2 therapyL A Everse, M R Bernsen, H F Dullens, et al.
European Journal of Cancer|January 1, 1979
Anti-tumour effect of chlorambucil-antibody complexes in a murine melanoma systemH F Dullens, R A De Weger, C Vennegoor, et al.
Infection and Immunity|December 1, 1985
Antibacterial resistance, macrophage influx, and activation induced by bacterial rRNA with dimethyldioctadecylammonium bromideR Gonggrijp, W J Mullers, H F Dullens, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive miceH F Dullens, W Vuist, M Van der Maas, et al.
Journal of the National Cancer Institute|January 1, 1975
Therapy with antibody-coated immune and hyperimmune peritoneal cells in a murine lymphoma systemH F Dullens, R A De Weger, R A Woutersen, et al.
Pageof 7